Prostate Cancer - Results from #1080

Beyond the Abstract - Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer, by Mariela Varsavsky, MD, PhD, et al January 13, 2012

Beyond the Abstract - Localising prostate cancer: Comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy, by Maximilien C. Goris Gbenou, MD January 10, 2012

Beyond the Abstract - Pre-treatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer, by Kathy Gilbert, MS, MBA December 22, 2011

Beyond the Abstract - Optimizing prostate cancer detection during biopsy by standardizing the amount of tissue examined per core, by John P. Sfakianos, MD December 21, 2011

Beyond the Abstract - Old issues and new perspectives on prostate cancer hormonal therapy: The molecular substratum, by Leonardo Oliveira Reis, MD., MSc., PhD December 9, 2011

Beyond the Abstract - Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer, by Pinkawa M, MD., Et Al December 8, 2011

Beyond the Abstract - Anatomical and clinical predictors of acute bowel toxicity in whole pelvis irradiation for prostate cancer with Tomotherapy, by Fiorino C, MD., Et Al December 6, 2011

Beyond the Abstract - PET and PET/CT in radiation treatment planning for prostate cancer, by Micheal Pinkawa, MD., Et Al December 2, 2011

Beyond the Abstract - Reirradiation of prostate cancer with rectum preservation: Eradicative high-dose-rate brachytherapy with natural type hyaluronate injection, by Kazushi Kishi, MD, PhD., Et Al December 1, 2011

Beyond the Abstract - Robot-assisted radical prostatectomy in patients with previous renal transplantation , by D. Duane Baldwin, MD., Et Al November 22, 2011

Beyond the Abstract - Prostate derived ETS factor (PDEF): A putative tumor metastasis suppressor, by Joshua J. Steffan, Ph.D. and Hari K. Koul, M.Sc., PhD, FACN, FASN November 22, 2011

Beyond the Abstract - Clinical trial update and novel therapeutic approaches for metastatic prostate cancer , by Jenny Liao Persson, PhD., Et Al November 18, 2011

Beyond the Abstract - Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration , by Takumi Takeuchi, MD November 17, 2011

Beyond the Abstract - Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions , by Alexandre de la Taille, MD., Et Al November 16, 2011

Beyond the Abstract - Impact of race on disease recurrence following prostate Brachytherapy, by Kosj Yamoah MD., PhD November 15, 2011

Beyond the Abstract - Quality of life, behavioral problems, and marital adjustment in the first year after radical prostatectomy , by Rodrigo Fernando Pereira, Ph.D., Et Al November 15, 2011

Beyond the Abstract - Comparative Toxicity and Dosimetric Profile of Whole-Pelvis Versus Prostate Bed-Only Intensity-Modulated Radiation Therapy after Prostatectomy, by Curtiland Deville, MD November 14, 2011

Beyond the Abstract - Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients, by Kenneth Nepple, MD November 10, 2011

Beyond the Abstract - Development and validation of a utility weighting function for the PORPUS- Patient Oriented Prostate Utility Scale, by Karen E. Bremner, BSc, et al November 8, 2011

Beyond the Abstract - Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment November 4, 2011

Page 55 of 58